Genomics: Fuelling Canada’s growing bioeconomy11:45am-1:30pm | The Fairmont Château Laurier - 1 Rideau Street, Ottawa
Genomes are made out of DNA and contain the “code of life” of any living organism. The work of cracking these codes is unleashing innovations that are helping to address some of the most critical challenges facing the world today, including food security, adaptation to climate change, energy demand and human health. Through a sustained and focused investment of more than $2.3 billion in genomics over the past 14 years, Canada finds itself among world leaders in this field. Further, we are now perfectly positioned to reap the social and economic benefits enabled by this revolutionary technology across all sectors of the life science-based industries, collectively constituting the bio economy. Genome Canada President and CEO, Pierre Meulien, will discuss this game-changing field of science and technology and what it means for Canada.
Individual seat: $89 +HST
Table (seats 10): $801 +HST
Individual: $110 +HST
Table (seats 10): $990 +HST
President and CEO
Pierre Meulien was appointed President and CEO of Genome Canada in 2010.
Prior to this appointment, Dr. Meulien was Chief Scientific Officer for Genome British Columbia (2007-2010), where he promoted the organization’s ongoing scientific strategy, focusing on the science of genomics, proteomics and bioinformatics within the larger realm of biotechnology and life sciences. He was also responsible for facilitating the translation of genome-based technologies into end-user communities across many life-science sectors.
From 2002-07, Dr. Meulien was the founding CEO of the Dublin Molecular Medicine Centre (now Molecular Medicine Ireland), which linked the three medical schools and six teaching hospitals in Dublin to build a critical mass in molecular medicine and translational research. The Centre managed the €45 million “Program for Human Genomics” financed by the Irish government and was responsible for coordinating the successful application for the first Wellcome Trust-funded Clinical Research Centre to be set up in Ireland.
For 20 years, Dr. Meulien has managed expert research teams with organizations including Aventis Pasteur, both in Toronto (Senior Vice President of R&D) and in Lyon, France (Director of Research). He also spent seven years with the French biotechnology company Transgene in Strasbourg, France, as a research scientist and member of the management team.
Dr. Meulien received his PhD from the University of Edinburgh and held a post-doctoral appointment at the Institut Pasteur in Paris.